Status:
COMPLETED
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
50-70 years
Brief Summary
The purpose of the study is to evaluate quality of life (Qol) in postmenopausal HR (+) EBC patients during adjuvant AIs treatment in terms of: the change of the trial outcome index (TOI) of the FACT-B...
Eligibility Criteria
Inclusion
- Postmenopausal women ≤ 70 years old, with histologically proven HR (+) early breast cancer.
- Undergoing upfront AIs adjuvant treatment within 7 days.
Exclusion
- Patients who disagree to participate this study
- Patients who, for whatever reason (eg, confusion, infirmity), are unlikely to comply with trial requirements.
- The AIs have not been approved by SFDA for the indication of upfront adjuvant endocrine therapy in early breast cancer.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
494 Patients enrolled
Trial Details
Trial ID
NCT01144572
Start Date
July 1 2010
End Date
October 1 2013
Last Update
February 14 2014
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Shenzhen, Guangdong, China
4
Research Site
Guiyang, Guizhou, China